-
Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa Hopledo® is already approved and marketed in the United States as CREXONT®, providing established regulatory and commercial experience as the therapy advances toward European approval More than…
-
The Developing Doctor Launches CME-Accredited Course to Enhance Physician Wellbeing
Iowa City, IOWA, June 24, 2026 (GLOBE NEWSWIRE) — The Developing Doctor has unveiled its latest self-paced course, “Mastery & Wellness: How to Thrive as a Physician,” now approved for 12 physician CME credits. This course is jointly provided with the Postgraduate Institute for Medicine (PIM), making it eligible for reimbursement through most institutional CME…
-
Chiesi Global Rare Diseases Announces European Commission Approval of LOJUXTA® (lomitapide) ▼ Capsules for Paediatric Use in Homozygous Familial Hypercholesterolaemia (HoFH)
European Commission approval expands the indication of lomitapide in the European Union (EU) to include children 5 years of age and older with HoFH, an ultra-rare genetic disorder affecting LDL-cholesterol levels June 05, 2026 02:00 ET | Source: Chiesi Global Rare Diseases PARMA, Italy, June 05, 2026 (GLOBE NEWSWIRE) — Chiesi Global Rare Diseases, a…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.
